Trials / Completed
CompletedNCT04006145
A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH
A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study to Explore the Efficacy and Safety of Elobixibat in Adults With Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 47 (actual)
- Sponsor
- Albireo · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Double-blind, randomized, placebo-controlled study to explore the efficacy and safety of elobixibat compared to placebo in adults with NAFLD (nonalcoholic fatty liver disease) or NASH (nonalcoholic steatohepatitis)
Detailed description
A total of 15 investigators at 15 sites received institutional review board (IRB)/ethics committee (EC) approval to participate in this study and enrolled at least 1 participant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Elobixibat | Elobixibat is a small molecule and a potent inhibitor of the ileal bile acid transporter (iBAT). |
| DRUG | Placebo oral tablet | Placebo identical in appearance to active drug |
Timeline
- Start date
- 2019-06-06
- Primary completion
- 2020-06-26
- Completion
- 2020-07-15
- First posted
- 2019-07-05
- Last updated
- 2026-02-05
- Results posted
- 2021-09-27
Locations
10 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04006145. Inclusion in this directory is not an endorsement.